SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy

SIMPLE SUMMARY: Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly receiving neoadjuvant therapy (NAT) with the aim of improving patient care. However, complete tumor regression remains rare, and there is a dire need for biomarkers that can predict responses to NAT. SMAD4 is a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Racu, Marie-Lucie, Bernardi, Dana, Chaouche, Aniss, Zindy, Egor, Navez, Julie, Loi, Patrizia, Maris, Calliope, Closset, Jean, Van Laethem, Jean-Luc, Decaestecker, Christine, Salmon, Isabelle, D’Haene, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417261/
https://www.ncbi.nlm.nih.gov/pubmed/37568581
http://dx.doi.org/10.3390/cancers15153765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417261/
https://www.ncbi.nlm.nih.gov/pubmed/37568581
http://dx.doi.org/10.3390/cancers15153765

Ejemplares similares